Kiora Pharmaceuticals Inc
KPRX
Company Profile
Business description
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.
Contact
332 Encinitas Boulevard
Suite 102
EncinitasCA92024
USAT: +1 858 224-9600
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
12
Stocks News & Analysis
stocks
More US tech stocks look cheap as the market rotates
Meanwhile, value-leaning areas of the market, including industrials and energy stocks, are moving out of undervalued territory.
stocks
Earnings Losers: GYG, DMP & LLC slump on souring market sentiment
The results that fell short of market expectations.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,430.60 | 10.10 | 0.11% |
| CAC 40 | 8,436.13 | 144.62 | -1.69% |
| DAX 40 | 24,806.53 | 477.73 | -1.89% |
| Dow JONES (US) | 48,977.92 | 521.28 | -1.05% |
| FTSE 100 | 10,806.22 | 104.33 | -0.96% |
| HKSE | 26,059.85 | 321.17 | -1.22% |
| NASDAQ | 22,668.21 | 210.17 | -0.92% |
| Nikkei 225 | 58,057.24 | 696.15 | -1.18% |
| NZX 50 Index | 13,656.65 | 14.06 | -0.10% |
| S&P 500 | 6,878.88 | 29.98 | -0.43% |
| S&P/ASX 200 | 9,200.90 | 19.20 | 0.21% |
| SSE Composite Index | 4,182.59 | 19.71 | 0.47% |